HDL and coronary heart disease—novel insights
Crossref DOI link: https://doi.org/10.1038/nrcardio.2014.128
Published Online: 2014-09-02
Published Print: 2014-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Landmesser, Ulf
Text and Data Mining valid from 2014-09-02
Article History
First Online: 2 September 2014
Competing interests
: U.L. has received research support, honoraria, or consultant fees from Amgen, Astra Zeneca, Merck Sharp & Dohme, Pfizer, Roche, and Sanofi-Aventis.